The inactivation of the E-cadherin-mediated cell adhesion system plays a critical role in the development of human cancers. This system, which is essential for maintaining cell-cell adhesion and tissue structure, is often disrupted in cancer cells, leading to reduced adhesion, loss of cell polarity, and increased invasiveness. The inactivation can occur through various mechanisms, including genetic mutations, epigenetic changes such as CpG methylation, and abnormal tyrosine phosphorylation of β-catenin. Genetic alterations in E-cadherin and its associated proteins, such as α-catenin and β-catenin, have been identified in multiple human cancers. These mutations can lead to the loss of cell-cell adhesion and contribute to the invasive and metastatic properties of tumors. Additionally, reduced expression of E-cadherin is associated with decreased cell adhesion and increased invasiveness. Epigenetic regulation, such as CpG methylation, can silence the E-cadherin gene, further contributing to the loss of adhesion. Aberrant tyrosine phosphorylation of β-catenin, often mediated by oncogenes like c-erbB-2, can disrupt the interaction between β-catenin and E-cadherin, leading to reduced cell adhesion and promoting tumor invasion and metastasis. The β-catenin-Wnt signaling pathway is also involved in the regulation of cell adhesion and tumor progression. Mutations in the APC gene, which normally regulates β-catenin levels, can lead to increased β-catenin activity and contribute to cancer development. Overall, the inactivation of the E-cadherin-mediated cell adhesion system through multiple mechanisms is a key factor in the progression of human cancers, influencing both early and late stages of carcinogenesis. Understanding these mechanisms is essential for developing effective strategies to prevent and treat cancer.The inactivation of the E-cadherin-mediated cell adhesion system plays a critical role in the development of human cancers. This system, which is essential for maintaining cell-cell adhesion and tissue structure, is often disrupted in cancer cells, leading to reduced adhesion, loss of cell polarity, and increased invasiveness. The inactivation can occur through various mechanisms, including genetic mutations, epigenetic changes such as CpG methylation, and abnormal tyrosine phosphorylation of β-catenin. Genetic alterations in E-cadherin and its associated proteins, such as α-catenin and β-catenin, have been identified in multiple human cancers. These mutations can lead to the loss of cell-cell adhesion and contribute to the invasive and metastatic properties of tumors. Additionally, reduced expression of E-cadherin is associated with decreased cell adhesion and increased invasiveness. Epigenetic regulation, such as CpG methylation, can silence the E-cadherin gene, further contributing to the loss of adhesion. Aberrant tyrosine phosphorylation of β-catenin, often mediated by oncogenes like c-erbB-2, can disrupt the interaction between β-catenin and E-cadherin, leading to reduced cell adhesion and promoting tumor invasion and metastasis. The β-catenin-Wnt signaling pathway is also involved in the regulation of cell adhesion and tumor progression. Mutations in the APC gene, which normally regulates β-catenin levels, can lead to increased β-catenin activity and contribute to cancer development. Overall, the inactivation of the E-cadherin-mediated cell adhesion system through multiple mechanisms is a key factor in the progression of human cancers, influencing both early and late stages of carcinogenesis. Understanding these mechanisms is essential for developing effective strategies to prevent and treat cancer.